Operates a hub-and-spoke network of Ayurvedic hospitals and sells Ayurvedic medicines and OTC wellness products. The Healthcare Services segment, which runs inpatient, outpatient, daycare and virtual-OPD treatments across hospitals, contributed 47.8% of FY26 revenue (₹383.4 crore). The Ayurvedic Products and Medicines segment, which makes and sells items like the Entero and NutriRoz OTC lines plus new pain-relief patches, contributed 51.9% (₹415.7 crore). Distribution for OTC products is being scaled through an Entero partnership that gives access to 1.25 lakh of India's 9 lakh chemists. Diagnostics inside the hospitals are run through a partnership with Chandan, currently at 34 centres generating ₹3 lakh/day and scaling to 64. Expansion includes 2,700-2,800 beds under development toward a 7,000-10,000 bed target over 3-5 years, plus international operations in UAE, Kazakhstan and Nepal. Other operating expenses (26.5% of revenue) and employee costs (18.5%) are the largest disclosed cost lines; materials cost is reported at 0.0% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Ayurvedic Products and Medicines (52%), Ayurvedic Healthcare Services (48%), Others (0%). Asset-light, capital-light expansion of an Ayurvedic hospital chain and OTC wellness products franchise.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 801 |
| EBITDA (ex other income) | 349 |
| margin % | 43.6 |
| Owners' profit | 222 |
| EPS, as reported (₹) | 17.84 |
| ROE % · ROCE % | 47.5 · 54.5 |
| Debt / equity (x) | 0.00 |
| Cash from operations | 254 |
| Capex | (34) |
| ₹ crore | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 174 | 190 | 222 | 216 | 224 |
| Profit before tax | 69 | 79 | 89 | 61 | 88 |
| Net profit | 51 | 59 | 67 | 45 | 66 |
| EPS (₹) | 4.13 | 4.73 | 5.36 | 3.63 | 5.30 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Ayurvedic products/ medicines | 118 | 27.0 |
| Ayurvedic healthcare services | 95 | 21.8 |
| Others | 2 | 0.5 |
| Ayurvedic products/medicines | 122 | 27.8 |
| Ayurvedic Healthcare Sevices | 100 | 22.8 |
| Total, before eliminations | 437 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| JEENA SIKHO LIFECARE LTD ◆ | 6,364 | 26.9 | 13.63 | 17.7 | 47.5 | 52.2 | — | 47.4 |
| KAYA LIMITED | 506 | — | — | — | 63.0 | (91.1) |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Lucknow hospital launch delayed to December 2026 | capex operations | high | — | — |
| 9 Sept 2026 · Postponement of new Day Care Clinic launch in Ayodhya | capex operations | medium | — | — |
| 8 Sept 2026 · NABH accreditation received for Pune Panchakarma hospital | business updates | medium | — | — |
| 5 Sept 2026 · JSLL launches two new Ayurvedic products for domestic market | business updates | medium | — | — |
| 5 Sept 2026 · Newspaper notice published for 9th Annual General Meeting and e-voting details | compliance | minimal | — | — |
| 4 Sept 2026 · 9th AGM notice and FY26 annual report web-link shared | compliance | minimal | — | — |
| 4 Sept 2026 · Jeena Sikho Lifecare submits BRSR and Annual Report for FY26 | compliance | low | — | — |
| 4 Sept 2026 · Jeena Sikho Lifecare 9th AGM notice and FY26 Integrated Annual Report | board shareholder meetings | medium | — | — |
| 4 Sept 2026 · 9th AGM notice on Sep 28, 2026 with Rs 4.50 dividend and director changes | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Jeena Sikho Lifecare launches 6 new Ayurvedic healthcare products | business updates | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| (4.1) |
| (12.4) |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 26.9 | 26.6 | 47 of 91 | 49% |
| P/B | 13.6 | 2.0 | 79 of 83 | 5% |
| ROCE | 52.2 | 5.4 | 4 of 101 | 97% |
| ROE | 47.5 | 5.8 | 4 of 87 | 97% |
| Debt / Equity | 0.0 | 0.1 | 22 of 87 | 74% |
| EBITDA margin | 47.4 | 23.4 | 14 of 85 | 85% |
| Revenue growth | 28.8 | 12.1 | 15 of 89 | 84% |
| Profit growth | 28.5 | 17.5 | 37 of 83 | 56% |
| Market cap | 6364 | 388 | 18 of 103 | 83% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
